Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 8/20 | 0.37 |
| ▸ | CA2 | P00918 | 8/20 | 0.37 |
| ▸ | CA12 | O43570 | 4/20 | 0.37 |
| ▸ | CA9 | Q16790 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.36 |
| ▸ | CPB1 | P15086 | 2/20 | 0.36 |
| ▸ | STK17B | O94768 | 1/20 | 0.36 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3838561 | 1.00 | SIGMAR1 (0.38) | SIGMAR1CA1CA2CA12CA9 | |
| SCHEMBL14631186 | 0.80 | SIGMAR1 (0.40) | SIGMAR1CA1CA2CA12CA9 | |
| SCHEMBL14631535 | 0.80 | SIGMAR1 (0.40) | SIGMAR1CA1CA2CA12CA9 | |
| SCHEMBL14631187 | 0.80 | SIGMAR1 (0.40) | SIGMAR1CA1CA2CA12CA9 | |
| SCHEMBL19158590 | 0.79 | CPB2 (0.40) | SIGMAR1CA1CA2MEN1GAA | |
| SCHEMBL14631226 | 0.78 | CPB2 (0.38) | SIGMAR1CA1CA2MEN1GAA | |
| SCHEMBL14630714 | 0.78 | CPB2 (0.39) | SIGMAR1MEN1GAAKMT2ACPB2 | |
| SCHEMBL20893299 | 0.78 | CPB2 (0.39) | SIGMAR1MEN1GAAKMT2ACPB2 | |
| SCHEMBL14631230 | 0.78 | CPB2 (0.38) | SIGMAR1CA1CA2MEN1GAA | |
| SCHEMBL14630708 | 0.78 | CPB2 (0.39) | SIGMAR1MEN1GAAKMT2ACPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1311488-B1 | SUBSTITUTED IMIDAZOLES AS TAFIA INHIBITORS | PFIZER LTD (GB) | 2009-11-04 | — | — | EP | disclosed |
| US-6949577-B2 | Pharmaceuticals | PFIZER, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20030236420-A1 | Pharmaceuticals | ALLERTON CHARLOTTE MOIRA NORFO (GB) | 2003-12-25 | — | — | US | disclosed |
| US-20020147229-A1 | Pharmaceuticals | PFIZER INC. | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147229-A1 | Pharmaceuticals | BDKRB1, TFPI, BDKRB2 | SIGMAR1 2243/4885CA1 4605/4885CA2 4181/4885 |
| US-20030236420-A1 | Pharmaceuticals | BDKRB1, TFPI, SERPINE1 | SIGMAR1 1855/4885CA1 4583/4885CA2 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.